Cargando…
Is there a difference in the effect between the ACEI and ARB on COVID‐19?
Autores principales: | Chen, Jie, Mei, Kaibo, Deng, Chao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Periodicals, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753763/ https://www.ncbi.nlm.nih.gov/pubmed/33205837 http://dx.doi.org/10.1002/clc.23474 |
Ejemplares similares
-
ARB might be superior to ACEI for treatment of hypertensive COVID‐19 patients
por: Zhao, Hong‐Jin, et al.
Publicado: (2021) -
Pharmacological rationale for antihypertensive drug choice on COVID‐19–affected patients: ACEI/ARB might not increase their susceptibility
por: Zhao, Hong‐Jin, et al.
Publicado: (2020) -
In-hospital use of ACEI/ARB is associated with lower risk of mortality and critic illness in COVID-19 patients with hypertension
por: Yuan, Yuan, et al.
Publicado: (2020) -
COVID-19 is more severe in patients with hypertension; ACEI/ARB treatment does not influence clinical severity and outcome
por: Hu, Jianhua, et al.
Publicado: (2020) -
ACEIs and ARBs and Their Correlation with COVID-19: A Review
por: Yehualashet, Awgichew Shewasinad, et al.
Publicado: (2020)